|
Volumn 44, Issue 3, 2012, Pages 791-793
|
Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALBINTERFERON ALPHA2B;
PEGINTERFERON;
RIBAVIRIN;
VIRUS RNA;
ADULT;
AGED;
ANTIVIRAL THERAPY;
ARTICLE;
DRUG DOSE INCREASE;
DRUG TOLERABILITY;
END STAGE LIVER DISEASE;
FEMALE;
GENOTYPE;
HEPATITIS C;
HUMAN;
LIVER CELL CARCINOMA;
LIVER TRANSPLANTATION;
MAJOR CLINICAL STUDY;
MALE;
MIXED INFECTION;
ORGAN DONOR;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
SCORING SYSTEM;
SEROLOGY;
SPLENECTOMY;
SURVIVAL RATE;
TREATMENT RESPONSE;
ADULT;
AGED;
ANTIVIRAL AGENTS;
FEMALE;
HEPACIVIRUS;
HEPATITIS C;
HUMANS;
INTERFERONS;
LIVER TRANSPLANTATION;
LIVING DONORS;
MALE;
MIDDLE AGED;
RIBAVIRIN;
RNA, VIRAL;
|
EID: 84859486325
PISSN: 00411345
EISSN: 18732623
Source Type: Journal
DOI: 10.1016/j.transproceed.2012.01.031 Document Type: Article |
Times cited : (9)
|
References (7)
|